Hadanny et al. (2020, Aging) is the cornerstone trial for HBOT as a cognitive-enhancement intervention in healthy older adults — distinct from injury-recovery use cases like TBI or stroke.
What the trial measured. Two primary outcome categories: standardized neuropsychological testing (attention, information processing speed, executive function including set-shifting, memory) and objective brain imaging (perfusion MRI for cerebral blood flow, voxel-based analysis). The trial deliberately paired cognitive testing with imaging to address the chronic concern that cognitive trials are vulnerable to practice effects and self-report bias.
Who was studied. Sixty-three healthy adults aged over 64 years (mean older), randomized to active HBOT (n=33) or control (n=30) for three months. Critically, the cohort excluded participants with prior brain pathology, mild cognitive impairment, or pathological cognitive decline — this is a healthy-aging trial, not a disease-recovery trial. The exclusion is what distinguishes Cognitive Performance from the TBI page on the Saturate site.
Protocol parameters. Sixty daily HBOT sessions at 2.0 ATA, 100% oxygen with 5-minute air breaks every 20 minutes, 90 minutes per session, 5 days per week, over three months. The 5-minute air-break design was deliberately included to engage the ‘oxygen paradox’ — the hyperoxic-hypoxic fluctuation that drives the regenerative response. This air-break design has since become standard for cognitive HBOT protocols.
Results. The group-by-time interaction in global cognitive function was statistically significant (p=0.0017). The largest individual effect sizes were attention (0.745) and information processing speed (0.788) — by Cohen convention, both are large effects. Set-shifting (a subset of executive function) also improved significantly. The HBOT group showed positive change while the control group showed slight deterioration over the same window — a consistent, directional pattern. Voxel-based perfusion MRI confirmed cerebral blood flow increases in the right superior medial frontal gyrus (BA10), bilateral supplementary motor area (BA6), middle frontal gyrus, and superior frontal gyrus — exactly the prefrontal regions where age-related decline is most pronounced.
Limitations. Sample size (n=63) is modest. Cohort was deliberately healthy older adults — generalizability to younger healthy adults is unclear because younger cohorts have less room to improve on the same measures (ceiling effect). Long-term durability beyond the immediate post-protocol window was not the primary focus; the broader Hachmo 2020 / Hachmo 2021 / Hadanny 2024 trial program addresses durability separately.
What it means in practice. The Hadanny 2020 protocol — 60 sessions at 2.0 ATA with 5-minute air breaks, 90-minute sessions, 5 days per week — is the directly-cited reference for the Cognitive Performance condition page. Cognitive enhancement is not an FDA-approved HBOT indication, so US insurance does not cover it; most users pay out of pocket at clinical chambers.
How it relates to other indexed trials. Hadanny 2020 is part of the same Israeli research-program cohort that produced Hachmo 2020 (telomere/senescent-cell clearance) and Hachmo 2021 (skin-biopsy substudy). The three papers together form the strongest single-cohort longevity evidence base in HBOT — cognitive, cellular, and dermal endpoints all moving in the same direction with the same protocol. The Marcinkowska 2022 systematic review of 42 cognitive-HBOT studies provides the broader cross-disorder context.
Source: PubMed PMID 32589613.